JBT Marel Corporation (JBTM): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/JBTM

Headline

Field	Value
Ticker	JBTM
Company	JBT Marel Corporation
Current price	$138.81/sh
Composition	Recurring 50% / Non-recurring 50%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (value-band context)	3.4%
Operating margin today	7.5%
Margin compression (value-band)	-4.1pp
Must persist for	7.3y
Multiple paid	32x operating income

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: high

Reference	Value
vs own history	+0.63σ
cohort percentile (of 222 peers)	79
sustained it ~7.3 years at this level	21%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	6.41x	5	expensive
Earnings	2.65x	2	expensive
Relative	1.71x	5	expensive
Growth	1.23x	2	expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.1%); the inversion above states its own rate.

Per-Model Detail (n=14)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$0.00	—	no	FCF base $0.0B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.1%, 7yr projection
DCF Exit Multiple	Growth	$97.91	1.42x	yes	Exit EV/EBITDA: 28.4x / 31.4x / 34.4x (bear / base = today's held flat / bull), 7yr
Relative Valuation	Relative	$81.05	1.71x	yes	P/E 25.63x (blended: static sector reference 18x + trailing (TTM) 43x), scenarios: 20.5x / 25.6x / 30.8x (bear / base = reference held flat / bull), EV/EBITDA 17.81x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$34.56	4.02x	yes	BV/sh $85.55, ROE (TTM) 3.7%, ke 9.3%
Two-Stage Excess Return	Asset	$21.65	6.41x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$131.94	1.05x	yes	Rev $3.9B, growth 30% (input: historical growth; tapered), Terminal P/S: 1.5x / 1.9x / 2.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$38.76	3.58x	yes	EPS $3.23, growth 2% (input: historical EPS growth), PEG=28.48 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$0.01	13881.00x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.16B × (1−25%) / WACC 8.1% → EPV (no growth) (excluded from median)
Residual Income	Asset	$16.40	8.46x	yes	BV $85.55 + 5yr PV of (ROE (TTM) 3.7% − Kₑ 9.3%) × BV; BV grows 2.4%/yr
Graham Number	Asset	$78.85	1.76x	yes	√(22.5 × EPS $3.23 × BVPS $85.55) — Graham's conservative floor
EV/EBITDA Relative	Relative	$31.42	4.42x	yes	EBITDA $0.29B × sector EV/EBITDA 12.0x
FCF Yield	Earnings	$0.01	13881.00x	yes	FCF $9.4M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$104.22	1.33x	yes	EPS $3.23 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$8.48	16.37x	yes	BV $85.55 × (ROIC 0.8% / WACC 8.1%)
P/Sales Sector	Relative	$185.12	0.75x	yes	Revenue $3.88B × sector P/S 2.5x
PEG Fair Value	Relative	$121.13	1.15x	yes	EPS $3.23 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$34.92	3.98x	yes	EPS $3.23 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$2.1b
Net debt / NOPAT (after-tax)	9.62x
Net debt / operating income (pre-tax)	7.22x
Share count CAGR (dilution)	13.0%
Burning cash	no

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• JBT Marel makes food and beverage processing equipment, formed by JBT's acquisition of Iceland's Marel, with revenue split roughly evenly between equipment sales (non-recurring) and the higher-margin aftermarket parts and service (recurring) stream.
• The balance sheet is the defining feature post-merger: net debt sits around $2.1 billion against trailing operating income near $290 million, more than seven times, and the share count rose about 13% as Marel shareholders were paid partly in stock.
• The first quarter of 2026 showed the integration working, with revenue up 10% and Protein Solutions adjusted EBITDA margin up more than 500 basis points to 21.7%, and management guiding 5% to 7% revenue growth for the year while flagging about $45 million of higher tariff costs.

Bull Case

The most revealing thing about JBT Marel right now is what the balance sheet says about management's conviction. The company took on substantial debt and issued meaningful equity to acquire Marel, lifting net debt to around $2.1 billion and the share count by roughly 13%, a bet-the-company move that a management team makes only when it believes the combined entity is worth far more than the parts. That confidence is being backed by the synergy execution: the company reports it is ahead of pace on its original target of $75 million in cumulative revenue synergies by 2027, and it is capturing cross-selling orders as the legacy JBT and Marel product lines are sold together. A leveraged acquirer delivering synergies ahead of plan is the signal that the debt was taken on for a reason that is paying off.

The business mix underneath the leverage is genuinely attractive. Revenue is split roughly evenly between equipment sales and recurring aftermarket parts and service, and the 10-K notes that the increase in organic revenue was "primarily the result of an increase in volume for recurring revenue." That recurring stream is the prize: once a processor installs JBT Marel equipment, it buys parts, service, and upgrades for years, a high-margin annuity that grows with the installed base. As the combined company expands that base globally, the recurring share should rise, lifting both margin and stability. Protein Solutions, the core segment, already lifted adjusted EBITDA margin more than 500 basis points year over year to 21.7% on volume leverage and Marel integration.

The operating momentum supports the deleveraging path the bull case requires. First-quarter revenue grew 10% with margins expanding 210 basis points, and management is targeting 5% to 7% organic growth with EBITDA margin above 20% by 2028. The food-processing end market is defensive, tied to global protein and packaged-food demand that grows with population and rising living standards rather than the economic cycle. The bull case is a leveraged but synergistic combination in a defensive, recurring-revenue-rich industry, where management's willingness to lever up is being validated by ahead-of-plan synergies and expanding margins, and where the high-margin aftermarket gives the cash flow to pay the debt down.

Bear Case

The external variable with the most leverage over JBT Marel today is trade policy, and the company has already quantified the hit. Management's 2026 guidance includes roughly $45 million of higher tariff costs, with mitigation expected to limit the margin impact to up to 50 basis points. For a company that manufactures heavy processing equipment with a global supply chain and a newly combined transatlantic footprint, JBT in the United States and Marel rooted in Iceland and Europe, tariffs and trade frictions are not a side issue; they tax the cross-border movement of components and finished machines that the merger was designed to optimize. A 50-basis-point estimated impact assumes successful mitigation, and trade policy can escalate faster than mitigation can be implemented.

The macro sensitivity compounds the trade risk on the demand side. Processing equipment is a capital good, and food and beverage producers defer large capital projects when financing is expensive or demand visibility is poor. Half of JBT Marel's revenue is exactly this non-recurring equipment sale, which is the cyclical part of the business; the recurring aftermarket is steadier, but new-equipment orders rise and fall with customers' capital budgets, which respond to interest rates and protein-market economics. The gross margin already slipped 140 basis points year over year in the prior period to 35.1%, a reminder that mix and cost pressures can move margins the wrong way even mid-integration.

The valuation and the leverage together leave little room for these external shocks. At $132.57 the asset, earnings-power, and peer-multiple methods all land far below the price, with the earnings-power value near zero on a reported basis; only the forward-growth methods reach the price, and they assume the synergies fully land and margins climb toward the 2028 target. The framework reads the name as elevated, with a fade signal tripped. Layered on top is the leverage: net debt above seven times trailing operating income is aggressive, and a tariff escalation or a capital-spending slowdown among food processors would pressure the cash flow the company needs to both integrate Marel and service that debt. The bear case is a richly priced, highly levered post-merger story whose biggest swing factor, trade policy, sits entirely outside management's control.

Valuation

JBT Marel is an elevated, post-merger case where the reported earnings are distorted by integration and the price leans on the forward-growth methods. At $132.57 the asset, earnings-power, and peer-multiple families all say richly valued: the earnings-power value is effectively zero on a reported basis (depressed by merger and amortization costs), the excess-return and residual-income methods land in the teens to mid-thirties, and EV/EBITDA near $31. Only the exit-multiple DCF (near $94) and the discounted-future-market-cap method (near $126) approach the price. The blended figure across all methods is near $39, reflecting how much of the price depends on the synergy-and-growth story rather than current economics.

The valuation therefore turns on the merger math. The reported revenue growth of 94% is an artifact of consolidating Marel, not organic expansion, so the relevant question is whether the combined company hits its synergy and margin targets. The inversion treats the price as a bet on durable compounding over a long runway, with an implied duration above ten years, which is a demanding assumption for a business mid-integration.

Leverage is the part of the valuation that cannot be set aside. Net debt of about $2.1 billion runs above seven times trailing operating income, with interest coverage around four times and a liquid-asset balance of only about $168 million, so the financial structure is stretched until the synergies lift cash flow and the debt is paid down.

Catalysts

JBT Marel's first quarter of 2026 was a constructive integration update. Revenue grew 10%, margins expanded 210 basis points, and the Protein Solutions segment lifted adjusted EBITDA margin more than 500 basis points year over year to 21.7% on poultry volume leverage and synergies in the Marel meat and fish businesses. Management said it is ahead of pace on its original $75 million cumulative revenue-synergy target by 2027 and continues to win cross-selling orders. Full-year 2026 guidance calls for 5% to 7% revenue growth with significant adjusted-EBITDA-margin improvement, alongside the longer-term target of 5% to 7% organic growth and above-20% EBITDA margin by 2028.

The catalysts from here are integration milestones and external risks in roughly equal measure. The things to watch on the positive side are the pace of synergy capture against the raised expectations, the growth of the high-margin recurring aftermarket revenue, and progress on deleveraging from the elevated post-merger net-debt level. The dominant external risk is trade policy: management has guided to about $45 million of higher tariff costs in 2026, and any escalation would pressure both costs and the cross-border supply chain. New-equipment order trends among food and beverage processors, which depend on customers' capital budgets, are the demand-side signal. The question that resolves the stock is whether the synergies and recurring-revenue growth lift cash flow fast enough to bring the leverage down and justify a price that already assumes the integration succeeds.

Peer Cohorts (Per Segment, With Filing Citations)

Protein Solutions (reported)

• MIDD (THE MIDDLEBY CORPORATION)
• FY2025 10-K: …Customers include some of the largest international food processing companies. A large portion of the company's revenues have been generated from producers of protein products such as bacon, salami and dry cure, sausage and hot dogs, egg bites, poultry, alternative protein, case ready, lunch meat and pet food, and…
• FY2025 10-K: …restaurant chains. The commercial foodservice equipment industry growth opportunities in the United States are driven by the development of new quick-service and casual-theme restaurant chain concepts, the expansion of foodservice into nontraditional locations such as convenience stores and retail outlets, as well as…
• GGG (GRACO INC.)
• FY2025 10-K: …then supply to their customers. Industrial The Industrial division designs and manufactures liquid finishing and advanced fluid dispensing equipment; pumps to move chemicals, petroleum, food, and other fluids; and systems, components, and accessories for the automatic lubrication of bearings, gears, and generators.…
• FY2025 10-K: …Outside of the U.S., our operations located in Australia, Belgium, Spain, Japan, Italy, Korea, India, the P.R.C., the United Kingdom and Brazil distribute our Company's products and reinforce our commitment to those regions. Our manufacturing capacity is sufficient for current business demand levels. In 2024 and…
• DOV (DOVER Corp)
• FY2025 10-K: …Our businesses that develop product identification, printing equipment and software solutions believe their customers expect a continuing rate of product innovation, performance improvement and reduction in total cost of ownership. The result has been downward pricing trends that can only be mitigated with the…
• FY2025 10-K: …service solutions used in textile, apparel, soft signage and specialty materials markets. Businesses within this segment leverage digital printing capabilities and operate business models that involve initial equipment and software sales followed by consumable, software, and service aftermarket revenue streams. Our…
• NDSN (NORDSON CORPORATION)
• FY2025 10-K: …drug infusion, IV & drug delivery, patient care, surgical and biopharma. • Surgical Solutions - Microplegia myocardial protection devices and related consumables used in cardiac surgical procedures. Advanced Technology Solutions This segment integrates our proprietary product technologies into the progressive stages…
• FY2025 10-K: …and laminating systems for the assembly of plastic, metal and wood products, for paper and paperboard converting applications and for the manufacturing of continuous roll goods. Key strategic markets include appliances, automotive components, building and construction materials, electronics, furniture, solar energy,…

Prepared Food and Beverage Solutions (reported)

• MIDD (THE MIDDLEBY CORPORATION)
• FY2025 10-K: …while delivering operational efficiencies. The company has identified these issues as key concerns for most of its customers. The company often identifies product improvement opportunities by working closely with customers on specific applications. Most research and development activities are performed by the…
• FY2025 10-K: …restaurant chains. The commercial foodservice equipment industry growth opportunities in the United States are driven by the development of new quick-service and casual-theme restaurant chain concepts, the expansion of foodservice into nontraditional locations such as convenience stores and retail outlets, as well as…
• SLGN (SILGAN HOLDINGS INC)
• FY2025 10-K: EBIT excluding corporate expense). Since 1987, we have improved our market position for our custom containers business, with net sales increasing at a compound annual growth rate of approximately 5.3 percent. We manufacture custom designed and stock plastic containers for food and beverage products, including peanut…
• FY2025 10-K: …of dispensing and specialty closures for the fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden markets. Our dispensing and specialty closures business provides customers with an extensive variety of innovative dispensing system solutions, including integrated dispensing…
• CCK (CROWN HOLDINGS, INC.)
• FY2025 10-K: …CUSTOMERS The Company's largest beverage can customers consist of many of the leading manufacturers and marketers of packaged consumer products in the world, including Anheuser-Busch InBev, Coca-Cola, Heineken, Keurig Dr Pepper, Molson Coors, Pepsi-Cola, and Refresco, among others. In addition to sales to Coca-Cola…
• FY2025 10-K: …engineering services and technical support. These capabilities facilitate (1) the identification of new and/or expanded market opportunities by working directly with customers to develop new packaging products or enhance existing packaging products through the application of new technologies that better differentiate…
• NDSN (NORDSON CORPORATION)
• FY2025 10-K: …drug infusion, IV & drug delivery, patient care, surgical and biopharma. • Surgical Solutions - Microplegia myocardial protection devices and related consumables used in cardiac surgical procedures. Advanced Technology Solutions This segment integrates our proprietary product technologies into the progressive stages…
• FY2025 10-K: …and cure surfaces. Our precision technology can be found in manufacturing facilities around the world, producing a wide range of goods for medical, electronics, consumer non-durable, industrial and other end markets. Equipment ranges from single-use components to manual, stand-alone units for low-volume operations to…
• DOV (DOVER Corp)
• FY2025 10-K: , retail fueling and vehicle wash establishments. • Our Imaging & Identification segment supplies precision marking and coding, product traceability, brand protection and digital textile printing equipment, as well as related consumables, software and services to the global packaged and consumer goods, pharmaceutical,…
• FY2025 10-K: Climate & Sustainability Technologies. For financial information about our segments and geographic areas, see Note 19 - Segment Information in the consolidated financial statements in Item 8 of this Form 10-K. Engineered Products Our Engineered Products segment provides a wide range of equipment, components, software,…
• SYM (SYM)
• FY2025 10-K: …our hardware and software development to offer better solutions to our customers that benefit their needs. Specifically, we intend to continue innovating our robust A.I.-powered robots alongside our proprietary software to continue to help our customers optimize operational efficiency. For example, we recently…
• FY2025 10-K: …nodes downstream in the supply chain. Our systems have a strategic impact for our customers and is mission critical for daily operations. We believe this will result in high rates of customer retention. Our BreakPack system can be integrated into our case handling system and be installed in a distribution center for…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

JBT Marel Q1 2026 earnings, Investing.com / AOL, May 2026 · JBT Marel Q1 2026 earnings, Globe and Mail, May 2026 · JBT Marel Q1 2026 earnings, Investing.com, May 2026